Your browser doesn't support javascript.
Management of Patients With Pulmonary Hypertension in COVID-19 Pandemic
Eastern Journal of Medicine ; 27(2):343-350, 2022.
Article in English | ProQuest Central | ID: covidwho-1876775
ABSTRACT
Pulmonary hypertension (PH) is a pulmonary vascular disease described by pulmonary arterial vasoconstriction and remodeling , which may lead to an increased pulmonary artery pressure with varying clinical course and severity depending on the etiology and eventually to right heart failure. Because of associated comorbidities, patients with PH are likely to face a potential risk of severe complications and mortality and unfortunately, they may have worse outcomes than other patients. COVID-19 emerges as one of the biggest threats facing society in this century. Besides its many medical consequences, the epidemic has psychological, social, and economic prices. [...]it is essential to understand its pathophysiology and clinical outcomes and to determine appropriate treatment strategies. Pathological characteristics of the endothelial cell structures of PH patients infected with COVID-19, down-regulation of angiotensin-converting enzyme 2 (ACE-2) receptors, which play a fundamental role in both the entry and replication of coronaviruses and also pulmonary arterial hypertension (PAH)-specific drugs used in its treatment may contribute to this (5,6).
Keywords
Search on Google
Collection: Databases of international organizations Database: ProQuest Central Language: English Journal: Eastern Journal of Medicine Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS

Search on Google
Collection: Databases of international organizations Database: ProQuest Central Language: English Journal: Eastern Journal of Medicine Year: 2022 Document Type: Article